Patents by Inventor Arisa Cale

Arisa Cale has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11939363
    Abstract: A range of therapeutic mRNA molecules expressible to provide a target polypeptide or protein. The RNA molecules can contain one or more 5-methoxyuridines and 5-methylcytidines. Further provided are DNA templates, which can be transcribed to provide a target mRNA, and can have altered nucleotides, such as reduced deoxyadenosines. Also provided are processes for making the therapeutic mRNA molecules. The RNA molecules can be translated in vitro or in vivo to provide an active polypeptide or protein. The RNA molecules can be included in a composition used for preventing, treating, or ameliorating at least one symptom of a disease or condition in a subject in need thereof.
    Type: Grant
    Filed: July 14, 2022
    Date of Patent: March 26, 2024
    Assignee: ARCTURUS THERAPEUTICS, INC.
    Inventors: Pattraranee Limphong, Kiyoshi Tachikawa, Padmanabh Chivukula, Daiki Matsuda, Arisa Cale
  • Publication number: 20230059111
    Abstract: A range of therapeutic mRNA molecules expressible to provide a target polypeptide or protein. The RNA molecules can contain one or more 5-methoxyuridines and 5-methylcytidines. Further provided are DNA templates, which can be transcribed to provide a target mRNA, and can have altered nucleotides, such as reduced deoxyadenosines. Also provided are processes for making the therapeutic mRNA molecules. The RNA molecules can be translated in vitro or in vivo to provide an active polypeptide or protein. The RNA molecules can be included in a composition used for preventing, treating, or ameliorating at least one symptom of a disease or condition in a subject in need thereof.
    Type: Application
    Filed: July 14, 2022
    Publication date: February 23, 2023
    Inventors: Pattraranee LIMPHONG, Kiyoshi TACHIKAWA, Padmanabh CHIVUKULA, Daiki MATSUDA, Arisa CALE
  • Patent number: 11407800
    Abstract: A range of therapeutic mRNA molecules expressible to provide a target polypeptide or protein. The RNA molecules can contain one or more 5-methoxyuridines and 5-methylcytidines. Further provided are DNA templates, which can be transcribed to provide a target mRNA, and can have altered nucleotides, such as reduced deoxyadenosines. Also provided are processes for making the therapeutic mRNA molecules. The RNA molecules can be translated in vitro or in vivo to provide an active polypeptide or protein. The RNA molecules can be included in a composition used for preventing, treating, or ameliorating at least one symptom of a disease or condition in a subject in need thereof.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: August 9, 2022
    Assignee: ARCTURUS THERAPEUTICS, INC.
    Inventors: Pattraranee Limphong, Kiyoshi Tachikawa, Padmanabh Chivukula, Daiki Matsuda, Arisa Cale
  • Publication number: 20210317468
    Abstract: This invention provides expressible polynucleotides, which can express a target protein or polypeptide. Synthetic mRNA constructs for producing a protein or polypeptide can contain one or more 5? UTRs, where a 5? UTR may be expressed by a gene of a plant. In some embodiments, a 5? UTR may be expressed by a gene of a member of Arabidopsis genus. The synthetic mRNA constructs can be used as pharmaceutical agents for expressing a target protein or polypeptide in vivo.
    Type: Application
    Filed: April 23, 2021
    Publication date: October 14, 2021
    Inventors: Pattraranee Limphong, Carlos G. Perez-Garcia, Kiyoshi Tachikawa, Padmanabh Chivukula, Arisa Cale, Angel I-Jou Leu, Jared Davis
  • Patent number: 11015204
    Abstract: This invention provides expressible polynucleotides, which can express a target protein or polypeptide. Synthetic mRNA constructs for producing a protein or polypeptide can contain one or more 5? UTRs, where a 5? UTR may be expressed by a gene of a plant. In some embodiments, a 5? UTR may be expressed by a gene of a member of Arabidopsis genus. The synthetic mRNA constructs can be used as pharmaceutical agents for expressing a target protein or polypeptide in vivo.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: May 25, 2021
    Assignee: Arcturus Therapeutics, Inc.
    Inventors: Pattraranee Limphong, Carlos G. Perez-Garcia, Kiyoshi Tachikawa, Padmanabh Chivukula, Arisa Cale, Angel I-Jou Leu, Jared Davis
  • Publication number: 20190002906
    Abstract: This invention provides expressible polynucleotides, which can express a target protein or polypeptide. Synthetic mRNA constructs for producing a protein or polypeptide can contain one or more 5? UTRs, where a 5? UTR may be expressed by a gene of a plant. In some embodiments, a 5? UTR may be expressed by a gene of a member of Arabidopsis genus. The synthetic mRNA constructs can be used as pharmaceutical agents for expressing a target protein or polypeptide in vivo.
    Type: Application
    Filed: May 31, 2018
    Publication date: January 3, 2019
    Inventors: Pattraranee Limphong, Carlos G. Perez-Garcia, Kiyoshi Tachikawa, Padmanabh Chivukula, Arisa Cale, Angel I-Jou Leu, Jared Davis
  • Publication number: 20180327471
    Abstract: A range of therapeutic mRNA molecules expressible to provide a target polypeptide or protein. The RNA molecules can contain one or more 5-methoxyuridines and 5-methylcytidines. Further provided are DNA templates, which can be transcribed to provide a target mRNA, and can have altered nucleotides, such as reduced deoxyadenosines. This invention also provides processes for making the therapeutic mRNA molecules. The RNA molecules can be translated in vitro or in vivo to provide an active polypeptide or protein.
    Type: Application
    Filed: February 27, 2018
    Publication date: November 15, 2018
    Inventors: Pattraranee Limphong, Kiyoshi Tachikawa, Padmanabh Chivukula, Daiki Matsuda, Arisa Cale